A New York Times article sheds light on recent evidence suggesting that those undergoing hip or knee replacement will do just as well with home therapy compared to inpatient rehabilitation following surgery.
Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission. Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.
The morbidity associated with osteoporosis-related fragility fractures imposes tremendous socioeconomic and medical impact on patients and society.
Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations. Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density. The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.
Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.
The NY Times points out "there is is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.
Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has delayed its' decision on baricitinib by issuing a complete response letter for baricitinib's New Drug Application.
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
